Virus microneutralisation assay

Virus microneutralisation assay is a cell-based method used to quantify the ability of antibodies in serum to neutralize a specific virus. Unlike the haemagglutination inhibition (HAI) assay, which only detects antibodies targeting the virus's ability to agglutinate red blood cells, the microneutralisation assay can detect a broader range of neutralizing antibodies. This makes it essential for emerging pathogens where HAI-specific-binding-sites may be mutated. The method is standardized under international guidelines such as WHO's vaccine-related protocols and ISO 20804. In the context of enterprise risk management, it serves as a critical tool for product efficacy verification, ensuring that vaccines or therapeutics meet the necessary potency standards before market release.

In enterprise risk management (ERM), the virus microneutralisation assay is applied through three key stages: Standardization, Verification, and Monitoring. First, companies must standardize the assay protocol, including the use of-reference-strains and standardized cell lines (e.g., MDCK cells). Second, the assay is used to verify the potency of each production batch, ensuring compliance with regulatory requirements like the FDA's Biological Products Control-21 CFR Part 610. Third, post-market surveillance uses this assay to monitor vaccine-resistant strains. For a vaccine manufacturer, this systematic application can reduce the risk of regulatory non-compliance by up to 40% and prevent costly product recalls by detecting potency-related issues before distribution.

Taiwan enterprises typically face three challenges: technical expertise, regulatory divergence, and high-cost infrastructure. First, the assay requires specialized skills in virology and bioinformatics; companies should invest in staff training or partner with specialized CROs. Second, the regulatory landscape in Taiwan (TFDA), China (NMPA), and Europe (EMA) differs significantly; the solution is to adopt the most stringent international standard as the baseline. Third, the cost of cell-culture-based assays is much higher than serological tests; companies should implement a risk-based testing strategy, prioritizing high-risk products for microneutralisation assays while using cheaper methods for routine monitoring. A phased implementation over 12 months is recommended to balance ROI and compliance.

Winners Consulting Services Co., Ltd. specializes in Virus microneutralisation assay for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact